On March 17, 2016 Innate Pharma SA (the "Company" – Euronext Paris: FR0010331421 – IPH) reported that new preclinical data will be presented at the American Association Of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2016 taking place from 16 to 20 April 2016, in New Orleans, Louisiana, USA (Press release, Innate Pharma, MAR 17, 2016, View Source [SID:1234509600]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These data supports the rationale of four of Innate’s clinical and preclinical programs:

One poster will present preclinical data supporting the rationale for combining an NKG2A checkpoint inhibitor with a PD-1 or a PD-L1 checkpoint inhibitor in mouse models;
One poster will present new data reinforcing the rationale for IPH4301, a first-in-class anti-MICA/B humanized antibody;
Three posters will present preclinical data on new discovery programs targeting CD73 and CD39, immune checkpoints regulating the adenosine pathway, including one poster reporting data generated by OREGA Biotech, Innate’s collaborator on the CD39 project.
Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma, said: "The AACR (Free AACR Whitepaper) annual meeting is one of the major events in our field. This year, we are proud to present 5 posters, demonstrating the progress of our pipeline and the excellence of Innate Pharma’s science. These data supports the rationale and the potential of our assets, and strengthens Innate’s unique positioning in the immuno-oncology field".

******

Beyond posters presentations, Innate Pharma’s team will be present with a booth (#2604) to receive its peers and the financial community at AACR (Free AACR Whitepaper).

Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma, will hold a conference call to the attention of analysts and portfolio managers to discuss the data published and Company’s innovative pipeline.

Time and dial in: Tuesday, April 19th 10:30am Eastern Time

USA: 888 504 7963

International: +1 719 325 2452

Access code: 1890466

*******

About the posters to be presented at the AACR (Free AACR Whitepaper) Annual Meeting 2016:

IPH4301, an antibody targeting MICA and MICB exhibits potent cytotoxic activity and immunomodulatory properties for the treatment of cancer

Permanent Abstract Number: 1491
Session Category: Immunology
Session Title: Immune Modulating Agents and Therapeutic Antibodies
Session Date and Time: Monday Apr 18, 2016 8:00 AM – 12:00 PM
Location: Convention Center, Halls G-J, Poster Section 25
Presented by Mathieu Bléry, PhD
NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model

Permanent Abstract Number: 2342
Session Category: Immunology
Session Title: Immune Checkpoints 1
Session Date and Time: Monday Apr 18, 2016 1:00 PM – 5:00 PM
Location: Convention Center, Halls G-J, Poster Section 26
Presented by Pascale André, PhD
Discovery and characterization of new original blocking antibodies targeting the CD73 immune checkpoint for cancer immunotherapy

Permanent Abstract Number: 2344
Session Category: Immunology
Session Title: Immune Checkpoints 1
Session Date and Time: Monday Apr 18, 2016 1:00 PM – 5:00 PM
Location: Convention Center, Halls G-J, Poster Section 26
Presented by Ivan Perrot, PhD
Disruption of the CD39 immune checkpoint pathway increases the efficacy of various anticancer therapies in syngeneic mouse models

Permanent Abstract Number: 3218
Session Category: Immunology
Session Title: Immune Checkpoints 2
Session Date and Time: Tuesday Apr 19, 2016 8:00 AM – 12:00 PM
Location: Convention Center, Halls G-J, Poster Section 25
Presented by Jérémy Bastid, PharmD, PhD (OREGA Biotech)
Preclinical development of a humanized blocking antibody targeting the CD39 immune checkpoint for cancer immunotherapy

Permanent Abstract Number: 3222
Session Category: Immunology
Session Title: Immune Checkpoints 2
Session Date and Time: Tuesday Apr 19, 2016 8:00 AM – 12:00 PM
Location: Convention Center, Halls G-J, Poster Section 25
Presented by Ivan Perrot, PhD